Impact of Hypertension and Cardiovascular Diseases to Immune Response in COVID-19 Vaccination: A Systematic Review
Downloads
To determine impact of hypertension and cardiovascular diseases towards effectivity and safety of COVID-19 vaccination. Systematic review based on PRISMA statement was done. Searching was conducted in PubMed, ScienceDirect, Scopus, and ProQuest and resulting in 6 studies involving 4,053 participants which deemed on good quality according to Joanna Briggs Institute tools for critical appraisal. After thorough analysis, we found that two out of four studies assessing mRNA-based vaccine found out that hypertension lower antibody response significantly. Two out of two studies assessing inactivated virus vaccine shown that hypertensive patients tend to have lower antibody titers compared to control. One of studies mentioned above found that antibody titer was not different between populations with cardiovascular diseases and control.Hypertension lessened response to COVID-19 vaccination regardless of vaccine type used. However, lack of studies on cardiovascular disease suggested that more studies should be conducted, along with hypertension, in-order to make meta-analysis possible to provide better evidence.
Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel). 202; 9(5): 467
Prasad S, Kalafat E, Blakeway H, Towsend R, O'Brien P, Morris E, et al. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. Nature Communications. 2022; 13: 2414
Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMD Med. 2022; 20(1): 200
Mohammed I, Nauman A, Paul P, Ganesan S, Chen K, Jalil S, et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum Vaccin Immunother. 2022; 18(1): 2027160
Gram MA, Embord H, Schelde AB, Friis N, Nielsen KF, Mousten-Helms I, et al. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the alpha, delta, or omicron SARS-CoV-2 variant: a nationwide Danish cohort study. 2022; 19(9): e1003992
Andrews N, Stowe J, Kirsebom F, Toffa S. COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022; 386: 1532–46
Mitsunaga T, Ohtaki Y, Seki Y, Yoshioka M, Mori H, Suzuka M, et al. The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan. PeerJ. 2021; 9: e12316
Falahi S, Kenarkoohi A. Host factors and vaccine efficacy: implications for COVID-19 vaccines. J Med Virol. 2022; 94(4): 1330–5
Block JP, Boehmer TK, Forrest CB, Carton TW, Lee GM, Ajani UA, et al. Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination – PCORnet, United States, January 2021–January 2022 [Internet}. CDC. 2022. Available from: https://www.cdc.gov/mmwr/volumes/71/wr/mm7114e1.htm
Antopolis S. COVID vaccines are safe for patients with cardiovascular disease [Internet]. ESC. 2022. Available from: https://www.escardio.org/The-ESC/Press-Office/Press-releases/COVID-vaccines-are-safe-for-patients-with-cardiovascular-disease
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic Reviews. 2021; 10: 89.
Checklist for cohort studies [Internet]. The Joanna Briggs Institute. Available from: https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Cohort_Studies2017_0.pdf
Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev. 2022; 38(1): e3465
Ebinger JE, Joung S, Liu Y, Wu M, Weber B, Claggett B, et al. Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis. BMJ Open. 2022; 12(5): e0599994
Delgado JF, Berenguer-Llergo A, Julia G, Navarro G, Espasa M, Rodriguez S, et al. Antibody response induced by BNT162b2 and mRNA-1273 vaccines against the SARS-CoV-2 in a cohort of healthcare workers. Viruses. 2022; 14: 1235
Soegiarto G, Wulandari L, Purnomosari D, Fahmita KD, Gautama HI, Hadmoko ST, et al. Hypertension is associated with antibody response and breakthrough infection in healthcare workers following vaccination with inactivated SARS-CoV-2. Vaccine. 2022; 40: 4046–56
Parthymou A, Habeos EE, Habeos GI, Deligakis A, Livieratos E, Marangos M, et al. Factors associated with anti-SARS-CoV-2 antibody titres 3 months post-vaccination with the second dose of BNT162b2 vaccine: a longitudinal observational cohort study in western Greece. BMJ Open. 2022; 12: e057084
Rifai A, Pratama MZ, Wahono CS, Kalim H. Association between the effectiveness and immunogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) with the presence of hypertension among healthcare workers. Clin Exp Hypertens. 2022.
Inoue T, Moran I, Shinnakasu R, Phan TG, Kurosaki T. Generation of memory B cells and their reactivation. Immunol Rev. 2018;283:138–49
Ji Q, Cheng G, Ma N, Huang Y, Lin Y, Zhou Q, Que B, Dong J, Zhou Y, Nie S, et al. Circulating Th1, Th2, and Th17 levels in hypertensive patients. Dis Markers. 2017;2017:7146290
Asadikaram G, Ram M, Izadi A, Sheikh Fathollahi M, Nematollahi MH, Najafipour H, Shahoozehi B, Mirhoseini M, Masoumi M, Shahrokhi N, et al. The study of the serum level of IL-4, TGF-β, IFN-γ, and IL-6 in overweight patients with and without diabetes mellitus and hypertension. J Cell Biochem. 2019;120(3):4147–57
Mikolajczyk TP, Guzik TJ. Adaptive Immunity in Hypertension. Curr Hypertens Rep. 2019;21:68
Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, Fujita T. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension. 2003 Jul;42:31–38
Mattson DL, Abais-Battad JM. T Cell immunometabolism and redox signaling in hypertension. Curr Hypertens Rep 2021;23(12):45
Moshfegh CM, Case AJ. The redox-metabolic couple of T lymphocytes: potential consequences for hypertension. Antioxid Redox Signal 2021;34 (12):915–35
Rai A, Narisawa M, Li P, Piao L, Li Y, Yang G, et al. Adaptive immune disorders in hypertension and heart failure: focusing on T-cell subset activation and clinical implications. J Hypertens 2020;38(10):1878–89
Tanase MD, Gosav ME, Radu S, Ouatu A, Rezus C, Ciocoiu M, et al. Arterial hypertension and interleukins: potential therapeutic target or future diagnostic marker?. Int J Hypertens. 2019; 2019. 1–17.
Maddaloni E, D'Onofrio L, Alessandri F, et al. Cardiometabolic multimorbidity is associated with a worse Covid"19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). Cardiovasc Diabetol. 2020; 19(1):164
Maddaloni E, D'Onofrio L, Alessandri F, et al. Clinical features of patients with type 2 diabetes with and without Covid"19: a case control study (CoViDiab I). Diabetes Res Clin Pract. 2020;169: 108454
Yang J, Zheng Y, Gou X. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis. Int J Infect Dis. 2020; 94: 91–5
Angeli F, Reboldi G, Trapasso M, Santilli G, Zappa M, Verdecchia P. Blood pressure increase following COVID-19 vaccination: a systematic overview and meta-analysis. J Cardiovasc Dev Dis. 2022; 9(5): 150
Khani E, Entezari-Maleki T. Hypertensive crisis following COVID-19 vaccination. J Clin Pharmacol. 2022; 62: 1047–8
Soegiarto G, Purnomosari D, Wulandari L, et al. Incidence of SARS-CoV-2 infection in hospital workers before and after vaccination programme in East Java, Indonesia-A retrospective cohort study. Lancet Reg Health Southeast Asia. 2023 Mar;10:100130.doi:10.1016/j.lansea.2022.100130. Epub 2022 Dec 12. PMID: 36531927; PMCID: PMC9742226.
Modin D, Claggett B, Jí¸rgensen ME, et al. Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study. J Am Heart Assoc. 2022 Mar 15;11(6):e021715. doi: 10.1161/JAHA.121.021715. Epub 2022 Feb 8. PMID: 35132866; PMCID: PMC90752
Ying CQ, Lin XQ, Lv L, et al. Intentions of Patients with Hypertension to Receive a Booster Dose of the COVID-19 Vaccine: A Cross-Sectional Survey in Taizhou, China. Vaccines (Basel). 2022 Sep 29;10(10):1635. doi: 10.3390/vaccines10101635. PMID: 36298500; PMCID: PMC9608070.
Zhang Y, Chen H, Lv J, et al. Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus. Vaccines (Basel). 2022 Jun 25;10(7):1020. doi: 10.3390/vaccines10071020. PMID: 35891184; PMCID: PMC9315836.
Copyright (c) 2023 Indonesian Journal of Tropical and Infectious Disease
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
